ReviewDiscover nano2026
Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of multidrug-resistant microbes, rapidly evolving viruses, and recurring pandemics underscores the urgent need for advanced vaccine technologies. Nanoparticle-based vaccines have emerged as a transformative approach capable of overcoming the major shortcomings of traditional immunization methods. Their nanoscale architecture allows precise antigen targeting, enhanced stability, and controlled release, leading to more potent and durable immune protection. These smart systems can carry multiple antigens or adjuvants, mimic natural pathogens, and efficiently activate immune cells to elicit strong humoral and cellular responses. Various nanoparticle types, lipid-based, polymeric, inorganic, and biomimetic, demonstrate broad potential against infectious, inflammatory, and neoplastic diseases in both humans and animals. However, critical barriers remain in mass production, regulatory harmonization, and long-term safety assurance. The integration of nanotechnology with artificial intelligence (AI) and bioengineering now enables rational vaccine design, predictive modeling, and personalized immunization strategies. AI-driven optimization of nanoparticle formulations and immune response prediction are accelerating translational progress. The convergence of these disciplines is shaping a new generation of vaccines that are safer, more effective, and adaptable to global health challenges, paving the way toward precision vaccination for the modern era.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.